Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study

BackgroundOndansetron is widely used for prophylaxis of postoperative nausea and vomiting (PONV) after general anesthesia. While previous studies have emphasized its early use, the effects of ondansetron in intensive care unit (ICU) patients following cardiac surgery remain unclear. This study inves...

Full description

Saved in:
Bibliographic Details
Main Authors: Feiyi Xu, Xun Gong, Wei Chen, Xiaomin Dong, Jiang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1511545/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850064337240064000
author Feiyi Xu
Feiyi Xu
Xun Gong
Wei Chen
Xiaomin Dong
Jiang Li
author_facet Feiyi Xu
Feiyi Xu
Xun Gong
Wei Chen
Xiaomin Dong
Jiang Li
author_sort Feiyi Xu
collection DOAJ
description BackgroundOndansetron is widely used for prophylaxis of postoperative nausea and vomiting (PONV) after general anesthesia. While previous studies have emphasized its early use, the effects of ondansetron in intensive care unit (ICU) patients following cardiac surgery remain unclear. This study investigates the association between postoperative ondansetron exposure and the risk of mortality, acute kidney injury (AKI), and postoperative atrial fibrillation (POAF) in ICU patients after cardiac surgery.MethodsWe conducted a retrospective cohort study utilizing data from the MIMIC-IV database. Adult patients who underwent cardiac surgery and were subsequently admitted to the ICU were included. Cox proportional hazards models were employed to assess the effect of ondansetron exposure on ICU and 28-day mortality. Multivariable logistic regression analyses examined the associations between ondansetron exposure and the incidence of AKI (2-day and 7-day) and POAF. Sensitivity analyses included Propensity Score Matching (PSM) and the inclusion of patients with ICU stays of less than 24 h to ensure robustness of results. Subgroup analyses explored the effects of age and other clinical factors, with interaction tests to examine differential impacts.ResultsA total of 7,170 were included. The incidence of AKI was 74.4% at 2 days and 76.7% at 7 days post-surgery. The 28-day postoperative mortality rate was 1.4%, while the ICU mortality rate was 1.0%. POAF occurred in 17.4% of the patients. Ondansetron exposure was not associated with 28-day mortality or ICU mortality (p > 0.05). However, after PSM, ondansetron exposure was significantly associated with an elevated risk of AKI at 2 days (OR 1.28, 95% CI 1.13–1.45, p < 0.001] and 7 days (OR 1.25, 95% CI 1.15–1.45, p < 0.001), as well as POAF (OR 1.20, 95% CI 1.04–1.39, p = 0.014).Subgroup analysis revealed a stronger association in patients aged over 65 years, where ondansetron was linked to an increased risk of 7-day AKI (OR 1.51, 95% CI 1.29–1.78, p < 0.001) and POAF (OR 1.31, 95% CI 1.12–1.53, p = 0.001). Interaction tests showed a significant interaction between ondansetron exposure and age (P for interaction = 0.018 for AKI and P for interaction = 0.02 for POAF). Sensitivity analyses, including patients with ICU stays of less than 24 h, confirmed the robustness of these findings.ConclusionIn ICU patients following cardiac surgery, postoperative use of ondansetron is associated with an increased risk of both 7-day AKI and POAF, particularly in patients aged 65 years and older. These findings suggest that the use of ondansetron in this population should be approached with caution, especially in elderly patients who may be more susceptible to these complications. Further research is needed to explore the mechanisms underlying the association between ondansetron and these adverse outcomes.
format Article
id doaj-art-e9b281f2fcd0492da35d466806a84ad3
institution DOAJ
issn 1663-9812
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-e9b281f2fcd0492da35d466806a84ad32025-08-20T02:49:19ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.15115451511545Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort studyFeiyi Xu0Feiyi Xu1Xun Gong2Wei Chen3Xiaomin Dong4Jiang Li5Department of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, ChinaUniversity of Pharmacy, Guilin Medical University, Guilin, Guangxi, ChinaDepartment of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, ChinaDepartment of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, ChinaDepartment of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, ChinaDepartment of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, ChinaBackgroundOndansetron is widely used for prophylaxis of postoperative nausea and vomiting (PONV) after general anesthesia. While previous studies have emphasized its early use, the effects of ondansetron in intensive care unit (ICU) patients following cardiac surgery remain unclear. This study investigates the association between postoperative ondansetron exposure and the risk of mortality, acute kidney injury (AKI), and postoperative atrial fibrillation (POAF) in ICU patients after cardiac surgery.MethodsWe conducted a retrospective cohort study utilizing data from the MIMIC-IV database. Adult patients who underwent cardiac surgery and were subsequently admitted to the ICU were included. Cox proportional hazards models were employed to assess the effect of ondansetron exposure on ICU and 28-day mortality. Multivariable logistic regression analyses examined the associations between ondansetron exposure and the incidence of AKI (2-day and 7-day) and POAF. Sensitivity analyses included Propensity Score Matching (PSM) and the inclusion of patients with ICU stays of less than 24 h to ensure robustness of results. Subgroup analyses explored the effects of age and other clinical factors, with interaction tests to examine differential impacts.ResultsA total of 7,170 were included. The incidence of AKI was 74.4% at 2 days and 76.7% at 7 days post-surgery. The 28-day postoperative mortality rate was 1.4%, while the ICU mortality rate was 1.0%. POAF occurred in 17.4% of the patients. Ondansetron exposure was not associated with 28-day mortality or ICU mortality (p > 0.05). However, after PSM, ondansetron exposure was significantly associated with an elevated risk of AKI at 2 days (OR 1.28, 95% CI 1.13–1.45, p < 0.001] and 7 days (OR 1.25, 95% CI 1.15–1.45, p < 0.001), as well as POAF (OR 1.20, 95% CI 1.04–1.39, p = 0.014).Subgroup analysis revealed a stronger association in patients aged over 65 years, where ondansetron was linked to an increased risk of 7-day AKI (OR 1.51, 95% CI 1.29–1.78, p < 0.001) and POAF (OR 1.31, 95% CI 1.12–1.53, p = 0.001). Interaction tests showed a significant interaction between ondansetron exposure and age (P for interaction = 0.018 for AKI and P for interaction = 0.02 for POAF). Sensitivity analyses, including patients with ICU stays of less than 24 h, confirmed the robustness of these findings.ConclusionIn ICU patients following cardiac surgery, postoperative use of ondansetron is associated with an increased risk of both 7-day AKI and POAF, particularly in patients aged 65 years and older. These findings suggest that the use of ondansetron in this population should be approached with caution, especially in elderly patients who may be more susceptible to these complications. Further research is needed to explore the mechanisms underlying the association between ondansetron and these adverse outcomes.https://www.frontiersin.org/articles/10.3389/fphar.2024.1511545/fullOndansetronacute kidney injurycardiac surgery28-day mortalitypostoperative atrial fibrillationMIMIC-IV
spellingShingle Feiyi Xu
Feiyi Xu
Xun Gong
Wei Chen
Xiaomin Dong
Jiang Li
Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
Frontiers in Pharmacology
Ondansetron
acute kidney injury
cardiac surgery
28-day mortality
postoperative atrial fibrillation
MIMIC-IV
title Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
title_full Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
title_fullStr Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
title_full_unstemmed Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
title_short Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
title_sort ondansetron use is associated with increased risk of acute kidney injury in icu patients following cardiac surgery a retrospective cohort study
topic Ondansetron
acute kidney injury
cardiac surgery
28-day mortality
postoperative atrial fibrillation
MIMIC-IV
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1511545/full
work_keys_str_mv AT feiyixu ondansetronuseisassociatedwithincreasedriskofacutekidneyinjuryinicupatientsfollowingcardiacsurgeryaretrospectivecohortstudy
AT feiyixu ondansetronuseisassociatedwithincreasedriskofacutekidneyinjuryinicupatientsfollowingcardiacsurgeryaretrospectivecohortstudy
AT xungong ondansetronuseisassociatedwithincreasedriskofacutekidneyinjuryinicupatientsfollowingcardiacsurgeryaretrospectivecohortstudy
AT weichen ondansetronuseisassociatedwithincreasedriskofacutekidneyinjuryinicupatientsfollowingcardiacsurgeryaretrospectivecohortstudy
AT xiaomindong ondansetronuseisassociatedwithincreasedriskofacutekidneyinjuryinicupatientsfollowingcardiacsurgeryaretrospectivecohortstudy
AT jiangli ondansetronuseisassociatedwithincreasedriskofacutekidneyinjuryinicupatientsfollowingcardiacsurgeryaretrospectivecohortstudy